A milestone review on how macrophages affect tumor growth

Cancer Research

Volumn 76, Issue 22, 2016, Pages 6439-6442

  Caux, Christophe ^a,b,c   Ramos, Rodrigo Nalio ^b,c   Prendergast, George C ^d   Bendriss Vermare, Nathalie ^b,c   Ménétrier Caux, Christine ^a,b,c  

^a University of Lyon EA 7426 Pathophysiology of Injury Induced Immunosuppression PI3   (France)

^b CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^c UNIVERSITÉ DE LYON   (France)

^d LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS; CELL DIFFERENTIATION; CELL INFILTRATION; CELL PROLIFERATION; DRUG TARGETING; HUMAN; INFLAMMATION; MACROPHAGE; MACROPHAGE FUNCTION; METASTASIS; NOTE; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR INVASION; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; ANIMAL; NEOPLASM; PATHOLOGY;

ANIMALS; HUMANS; MACROPHAGES; NEOPLASMS;

EID: 84995488274     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-16-2631     Document Type: Note

References (28)

1. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006;66:605-12.
2. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002;23:549-55.
3. Sunderkötter C, Beil W, Roth J, Sorg C. Cellular events associated with inflammatory angiogenesis in the mouse cornea. Am J Pathol 1991;138:931-9.
4. De Palma M, Venneri MA, Galli R, Sergi Sergi L, Politi LS, Sampaolesi M, et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005;8:211-26.
5. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer related inflammation. Nature 2008;454:436-44
6. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-99.
7. Lavin Y, Mortha A, Rahman A, Merad M.Regulation of macrophage development and function in peripheral tissues. Nat Rev Immunol 2015;15:731-44.
8. Wang Y, Colonna M. Interkeukin-34, a cytokine crucial for the differentiation and maintenance of tissue resident macrophages and Langerhans cells. Eur J Immunol 2014;44:1575-81.
9. Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity 2014;41:49-61
10. Biswas SK, Allavena P, Mantovani A. Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Semin Immunopathol 2013;35:585-600.
11. Colegio OR, Chu NQ, Szabo AL, Chu T, Rhebergen AM, Jairam V, et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 2014;513:559-63
12. Lewis CE, Harney AS, Pollard JW. The multifaceted role of perivascular macrophages in tumors. Cancer Cell 2016;30:18-25
13. Hughes R, Qian BZ, Rowan C, Muthana M, Keklikoglou I, Olson OC, et al. Perivascular M2 macrophages stimulate tumor relapse after chemotherapy. Cancer Res 2015;75:3479-91
14. Qian BZ, Zhang H, Li J, He T, Yeo EJ, Soong DY, et al. FLT1 signaling in metastasis-associated macrophages activates an inflammatory signature that promotes breast cancer metastasis. J Exp Med 2015;212:1433-48.
15. Granot Z, Fridlender ZG. Plasticity beyond cancer cells and the "immunosuppressive switch". Cancer Res 2015;75:4441-5.
16. Ruffell B, Coussens LM. Macrophages and therapeutic resistance in cancer. Cancer Cell 2015;27:462-72.
17. Ménétrier-Caux C, Montmain G, Dieu MC, Bain C, Favrot MC, Caux C, et al. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 1998;92:4778-91.
18. Hargadon KM. Tumor-altered dendritic cell function: implications for antitumor immunity. Front Immunol 2013;4:192.
19. Ostuni R, Kratochvill F, Murray PJ, Natoli G.Macrophages and cancer: from mechanisms to therapeutic implications. Trends Immunol 2015;36:229-39.
20. Cassier PA, Italiano A, Gomez-Roca CA, Le Tourneau C, Toulmonde M, Cannarile MA, et al. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. Lancet Oncol 2015;16:949-56.
21. Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 2013;23:249-62.
22. Gul N, van Egmon M. Antibody-dependent phagocytosis of tumor cells by macrophages: a potent effector mechanism of monoclonal antibody therapy of cancer. Cancer Res 2015;75:5008-13
23. Kaneda MM, Cappello P, Nguyen AV, Ralainirina N, Hardamon CR, Foubert P, et al. Macrophage PI3Kγ drives pancreatic ductal adenocarcinoma progression. Cancer Discov 2016;6:870-85.
24. Gunderson AJ, Kaneda MM, Tsujikawa T, Nguyen AV, Affara NI, Ruffell B, et al. Bruton tyrosine kinase-dependent immune cell cross-talk drives pancreas cancer. Cancer Discov 2016;6:270-85.
25. Weiskopf K, Weissman IL. Macrophages are critical effectors of antibody therapies for cancer. MAbs 2015;7:303-10.
26. Ugel S, De Sanctis F, Mandruzzato S, Bronte V. Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. J Clin Invest 2015;125:3365-76.
27. Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun 2016;7:12150.
28. Prendergast GC, Metz R, Muller AJ. Towards a genetic definition of 'cancer-associated' inflammation: role of the IDO pathway. Am J Pathol 2010;176:2082-7.